NCT06626620

Randomized Controlled Trial of Intravenous Magnesium Sulfate Versus Terbutaline for Children in the Management of Acute Exacerbation of Asthma

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 120 (actual)
• Sponsor: Muhammad Aamir Latif · Academic / Other
• Sex: All
• Age: 5 Years – 12 Years
• Healthy volunteers: Not accepted

Summary

This study aimed to fill this gap by comparing the effectiveness of intravenous magnesium sulfate versus terbutaline in children with acute asthma exacerbations, providing evidence-based guidance for clinicians in emergency settings.

Detailed description

Despite the established roles of both magnesium sulfate and terbutaline in the management of severe asthma exacerbations, there is limited comparative data on their efficacy and safety in the pediatric population. Understanding the relative benefits and risks of these therapies is crucial for optimizing treatment strategies and improving patient outcomes.

Conditions

• Acute Exacerbation of Asthma

Interventions

Type	Name	Description
DRUG	Magnesium Sulphate infusion	Received IV magnesium sulfate (50 mg/kg up to a maximum dose of 2 g) administered over 20 minutes
DRUG	Terbutaline Infusion	Received IV terbutaline (10 mcg/kg bolus followed by a continuous infusion of 0.4 mcg/kg/min) for up to 4 hours

Timeline

• Start date: 2024-01-01
• Primary completion: 2024-09-30
• Completion: 2024-09-30
• First posted: 2024-10-04
• Last updated: 2024-10-04

Locations

1 site across 1 country: Pakistan